Apr 27, 2020
Harmony Biosciences Expands Patients At The Heart Grant Program And Reinforces Its Commitment To Newly Uninsured Patients
Mar 25, 2020
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Nov 15, 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Sep 25, 2019
Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019
Sep 20, 2019
Harmony Biosciences Announces Recipients of 2019 Patients at the Heart Grant in Recognition of World Narcolepsy Day
May 09, 2019
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Mar 26, 2019
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Mar 20, 2019
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Nov 29, 2018
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
Oct 29, 2018
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Oct 09, 2018
New Survey Identifies Need For Increased Education About And New Treatment Options For Narcolepsy
Sep 27, 2018
Data On Abuse Potential Of Pitolisant Presented At 2018 European Sleep (ESRS) Congress
Sep 05, 2018
AWAKE Sleep Apnea Initiative Documents Life-altering Impacts of Sleep Apnea and Patients' Priorities for Treatment
Sep 05, 2018
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming International Narcolepsy Symposium
Jun 27, 2018
Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 03, 2018
Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
May 29, 2018
Sleep Apnea Patients Seek to Inform and Accelerate Medical Product Development
May 23, 2018
HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
May 10, 2018
Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting